---
type: source
title: "Calibrate GLP-1 + Behavioral Coaching: Interrupted Access Data Shows Behavioral Floor Effect (Endocrine Society 2025)"
author: "Calibrate (Endocrine Society presentation, 2025)"
url: https://www.joincalibrate.com
date: 2025-01-01
domain: health
secondary_domains: []
format: report
status: processed
processed_by: vida
processed_date: 2026-04-13
priority: medium
tags: [glp1, behavioral-wraparound, adherence, interrupted-access, weight-loss, calibrate]
extraction_model: "anthropic/claude-sonnet-4.5"
---

## Content

Calibrate employer-sponsored program data (n=17,475 members; interrupted access analysis from Endocrine Society 2025 presentation):

**Primary outcomes (uninterrupted access):**
- 12-month weight loss: 15.7% average
- 18-month: 17.3%
- 24-month: 17.9% — continued loss, not plateau
- Waist circumference reduction: avg 6 inches at 12 months
- Engagement metrics: 80% track weight weekly; 67% complete coaching sessions

**Interrupted access data (Endocrine Society 2025):**
- Members with treatment interruptions: 13.7% weight loss at 12 months vs. 17% uninterrupted
- At 24 months: 14.9% vs. 20.1% for uninterrupted
- Delta: ~2.2 percentage points at 12 months; ~5.2 percentage points at 24 months

**Interpretation of interrupted access data:**
Even when GLP-1 access is interrupted, Calibrate members maintained 13.7-14.9% weight loss. In context:
- Standard GLP-1 cessation data (STEP 4 trial): patients regained ~2/3 of lost weight within 1 year of stopping — typically implying substantial regain
- Calibrate interrupted access: maintaining 13.7% at 12 months suggests the behavioral program provides a significant floor below which weight does not revert
- The behavioral program appears to prevent full rebound even when medication is unavailable

**Calibrate program components (1-year employer-sponsored):**
- GLP-1 prescriptions
- Coaching on food, sleep, exercise, emotional health (four pillars)
- Regular check-ins and goal tracking

**Methodological notes:**
- n=17,475 is a substantial sample
- "Treatment interruptions" is company-defined — criteria not specified in available data
- Endocrine Society presentation (not yet peer-reviewed as standalone paper)
- Financial conflict: Calibrate is presenting its own program data

## Agent Notes
**Why this matters:** The interrupted access data is the most mechanistically interesting finding from Calibrate. If the behavioral floor holds even when GLP-1 is interrupted — preventing the typical ~2/3 weight regain — this is more compelling evidence than the WW and Noom persistence data. It's suggesting behavioral change actually happened, not just medication effect.

**What surprised me:** 13.7% weight loss at 12 months for members with treatment interruptions. I expected closer to the standard cessation pattern. If this is real (not just survivorship bias of healthiest members who had interruptions), it suggests behavioral coaching is producing durable lifestyle change beyond the medication window.

**What I expected but didn't find:** A control condition — Calibrate members without behavioral coaching who had treatment interruptions. Without this, we can't isolate whether the behavioral program caused the floor effect or whether Calibrate members are just more health-motivated than average GLP-1 users.

**KB connections:**
- Omada post-discontinuation data (same structural question — does behavioral program prevent full rebound?)
- GLP-1 continuous-delivery requirement debate
- Behavioral vs. pharmacological intervention durability framing (Sessions 20-22)

**Extraction hints:**
- Not a standalone extraction target — use as one of 3-4 data points in a claim about behavioral wraparound providing a durability floor
- The interrupted access finding is more interesting than the primary outcomes — specifically, that 13.7% maintenance at 12 months with interruptions is dramatically better than standard GLP-1 cessation data
- Confidence would be: EXPERIMENTAL — promising pattern, not replicated in controlled design

**Context:** Calibrate targets employer plans. Program cost ranges from $200-300+/month depending on employer negotiation. It's positioned as a higher-intensity, higher-cost program than standard GLP-1 prescribing. Sample is entirely employer-sponsored, which skews toward commercially insured, higher-income populations.

## Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: Behavioral wraparound durability floor; continuous-delivery requirement scope qualification
WHY ARCHIVED: Interrupted access data is the most mechanistically compelling evidence that behavioral coaching produces durable effect beyond the medication window; pairs with Omada post-discontinuation data as converging evidence
EXTRACTION HINT: Use the interrupted access data (not the primary outcomes) as the key finding — this is the novel contribution. The floor effect at 13.7% is the claim candidate.
